The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero
Synageva BioPharma Corp (GEVA)

Synageva BioPharma is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products. Its lead program, sebelipase alfa, is a recombinant human lysosomal acid lipase (LAL) under clinical investigation for the treatment of patients with early onset and late onset LAL Deficiency. In addition to sebelipase alfa, Co. is investigating protein therapeutic programs for other diseases, which are at different stages of preclinical development. These include two enzyme replacement therapies for other lysosomal storage disorders and additional programs for other life-threatening conditions.

Recommended for you: 25 S.A.F.E. Dividend Stocks
Company Name:  Synageva BioPharma Corp
Website:  www.synageva.com
Sector:  Biotechnology
Number of ETFs Holding GEVA:  24
Total Market Value Held by ETFs:  $93.18M
Total Market Capitalization:  $2.39B
% of Market Cap. Held by ETFs:  3.90%
July 30, 2014    1:00 AM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes



Strong Buy (3.64 out of 4)
78th percentile
(ranked higher than approx. 78% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Synageva BioPharma Corp (GEVA) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.